Nanotechnology Now

Our NanoNews Digest Sponsors

Home > News > Mission Pharmacal Obtains Observation Rights to Nanobac Life Sciences

August 11th, 2005

Mission Pharmacal Obtains Observation Rights to Nanobac Life Sciences

Abstract:
Nanobac Life Sciences, Inc. announced today that Mission Pharmacal Company, a global pharmaceutical company and leading kidney stone disease reference laboratory, executed an observation rights agreement with Nanobac Life Sciences to observe a multi-center collaboration involving researchers from Nanobac, the University of California, San Francisco (UCSF), and NASA's Johnson Space Center, to study kidney stone formation.

Source:
businesswire

Bookmark:

Related News Press

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

	The latest news from around the world, FREE

Premium Products
	Only the news you want to read!  Learn More
	Full-service, expert consulting  Learn More

Nanotechnology Now Featured Books

© Copyright 1999-2023 7th Wave, Inc. All Rights Reserved

PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE